Swedish Orphan Biovitrum AB (publ) (SOBI) - Total Assets
Based on the latest financial reports, Swedish Orphan Biovitrum AB (publ) (SOBI) holds total assets worth Skr81.26 Billion SEK (≈ $8.74 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore SOBI operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Swedish Orphan Biovitrum AB (publ) - Total Assets Trend (2002–2025)
This chart illustrates how Swedish Orphan Biovitrum AB (publ)'s total assets have evolved over time, based on quarterly financial data. See net assets of Swedish Orphan Biovitrum AB (publ) for net asset value and shareholders' equity analysis.
Swedish Orphan Biovitrum AB (publ) - Asset Composition Analysis
Current Asset Composition (December 2025)
Swedish Orphan Biovitrum AB (publ)'s total assets of Skr81.26 Billion consist of 21.5% current assets and 78.5% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr1.04 Billion | 1.5% |
| Accounts Receivable | Skr8.36 Billion | 12.4% |
| Inventory | Skr5.13 Billion | 7.6% |
| Property, Plant & Equipment | Skr1.63 Billion | 2.4% |
| Intangible Assets | Skr40.06 Billion | 59.4% |
| Goodwill | Skr9.02 Billion | 13.4% |
Asset Composition Trend (2002–2025)
This chart illustrates how Swedish Orphan Biovitrum AB (publ)'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Swedish Orphan Biovitrum AB (publ) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Swedish Orphan Biovitrum AB (publ)'s current assets represent 21.5% of total assets in 2025, a decrease from 74.1% in 2002.
- Cash Position: Cash and equivalents constituted 1.5% of total assets in 2025, down from 5.3% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, an increase from 0.0% in 2002.
- Asset Diversification: The largest asset category is intangible assets at 59.4% of total assets.
Swedish Orphan Biovitrum AB (publ) Competitors by Total Assets
Key competitors of Swedish Orphan Biovitrum AB (publ) based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
|
India | Rs443.12 Billion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥11.40 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
Swedish Orphan Biovitrum AB (publ) - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.70 | 0.98 | 0.84 |
| Quick Ratio | 0.47 | 0.65 | 0.43 |
| Cash Ratio | 0.00 | 0.08 | 0.03 |
| Working Capital | Skr-6.41 Billion | Skr-246.00 Million | Skr-1.26 Billion |
Swedish Orphan Biovitrum AB (publ) - Advanced Valuation Insights
This section examines the relationship between Swedish Orphan Biovitrum AB (publ)'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.73 |
| Latest Market Cap to Assets Ratio | 0.25 |
| Asset Growth Rate (YoY) | -10.6% |
| Total Assets | Skr67.43 Billion |
| Market Capitalization | $17.02 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Swedish Orphan Biovitrum AB (publ)'s assets below their book value (0.25x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Swedish Orphan Biovitrum AB (publ)'s assets decreased by 10.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Swedish Orphan Biovitrum AB (publ) (2002–2025)
The table below shows the annual total assets of Swedish Orphan Biovitrum AB (publ) from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr67.43 Billion ≈ $7.26 Billion |
-10.62% |
| 2024-12-31 | Skr75.44 Billion ≈ $8.12 Billion |
+1.91% |
| 2023-12-31 | Skr74.03 Billion ≈ $7.97 Billion |
+41.01% |
| 2022-12-31 | Skr52.50 Billion ≈ $5.65 Billion |
+7.88% |
| 2021-12-31 | Skr48.66 Billion ≈ $5.24 Billion |
+0.78% |
| 2020-12-31 | Skr48.28 Billion ≈ $5.20 Billion |
+5.75% |
| 2019-12-31 | Skr45.66 Billion ≈ $4.91 Billion |
+165.71% |
| 2018-12-31 | Skr17.18 Billion ≈ $1.85 Billion |
+57.60% |
| 2017-12-31 | Skr10.90 Billion ≈ $1.17 Billion |
+9.31% |
| 2016-12-31 | Skr9.97 Billion ≈ $1.07 Billion |
+20.02% |
| 2015-12-31 | Skr8.31 Billion ≈ $894.37 Million |
+30.45% |
| 2014-12-31 | Skr6.37 Billion ≈ $685.59 Million |
-2.28% |
| 2013-12-31 | Skr6.52 Billion ≈ $701.58 Million |
+3.18% |
| 2012-12-31 | Skr6.32 Billion ≈ $679.96 Million |
-5.69% |
| 2011-12-31 | Skr6.70 Billion ≈ $720.98 Million |
-5.23% |
| 2010-12-31 | Skr7.07 Billion ≈ $760.80 Million |
+151.99% |
| 2009-12-31 | Skr2.81 Billion ≈ $301.92 Million |
+8.79% |
| 2008-12-31 | Skr2.58 Billion ≈ $277.52 Million |
+32.36% |
| 2007-12-31 | Skr1.95 Billion ≈ $209.67 Million |
-6.23% |
| 2006-12-31 | Skr2.08 Billion ≈ $223.59 Million |
-23.84% |
| 2005-12-31 | Skr2.73 Billion ≈ $293.59 Million |
+12.73% |
| 2004-12-31 | Skr2.42 Billion ≈ $260.43 Million |
+1.94% |
| 2003-12-31 | Skr2.37 Billion ≈ $255.48 Million |
+19.15% |
| 2002-12-31 | Skr1.99 Billion ≈ $214.42 Million |
-- |
About Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with… Read more